Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

Video content above is prompted by the following:

• For patients with higher-risk myelodysplastic syndromes (MDS), what are some of the primary challenges in conducting research and developing novel therapies for this patient population?
• How do social support and logistical factors, such as the ability to access clinics for extended periods for injectable hypomethylating agents (HMAs), affect treatment adherence and outcomes in patients with higher-risk MDS?
• Given that HMAs are the backbone of treatment for higher-risk MDS, how do oral options such as decitabine-cedazuridine and other emerging therapies address the need for more convenient administration while maintaining efficacy?